Australia's Perdaman Pharma Seeks To Build Formulation Plant In India
This article was originally published in PharmAsia News
Executive Summary
Perdaman Pharmaceuticals, an Australian manufacturer of branded generics, plans to build a $181 million formulation facility In India, home country of the company's owner, Vikas Rambal